The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.

ABSTRACT:

Background

The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who were treated preoperatively with larotrectinib and underwent subsequent surgical resection.

Methods

A total of 24 children were treated on a pediatric phase 1 trial of larotrectinib (ClinicalTrials.gov identifier NCT02637687). Five children who had a documented TRK fusion sarcoma and underwent surgical resection were included in the current analysis. Tumor response (Response Evaluation Criteria In Solid Tumors [RECIST] version 1.1) and surgical outcomes were collected prospectively.

SUBMITTER: DuBois SG 

PROVIDER: S-EPMC6263791 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature